<DOC>
	<DOCNO>NCT01673724</DOCNO>
	<brief_summary>The purpose study determine whether pramipexole bromocriptine effective treatment non-motor symptom Parkinson 's Disease .</brief_summary>
	<brief_title>Pramipexole Bromocriptine Nonmotor Symptoms Early Parkinson 's Disease</brief_title>
	<detailed_description>PRIMARY OBJECTIVE Evaluate Improvement Nonmotor symptom scale ( NMSS ) Pramipexole Bromocriptine early Parkinson 's disease 24-week treatment SECONDARY OBJECTIVE - Evaluate improvement Depression one Nonmotor symptoms - Evaluate improvement clinical symptom two group - Evaluate improvement Quality Life two group</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Bromocriptine</mesh_term>
	<criteria>Parkinson 's disease patient accordance UK Queensquare Brain Bank modify Hoehn &amp; Yahr stage &lt; 3 Dopamine agent ( Levodopa , dopamine agonist ) naive patient , patient discontinue agent least four week screen case use dopamine agent administer . KMMSE &lt; 24 History druginduced Parkinsonism secondary parkinsonism History schizophrenia hallucination Requirement treatment antidepressant due depressive disorder Pregnant and/or breed woman Renal inadequacy</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>